pipette
ESEspañol

LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primates

Marie-Laure Arotçarena, Maria Fouka, Elena Georgia Gialinaki, Marianna Giannopoulou, H. Jadot, Morgane Darricau, Anna Lovisotto, Sandra Doveró, Vincent Planche, Elio Balpe, Mélyna Achour, Marie-Laure Thiolat, Nathalie Dutheil, Qin Li, Emilie Noe, Elsa Y. Pioli, Karim Harhouri, Rémy Steinschneider, Deniz Kirik, Nanna Møller Jensen, Poul Henning Jensen, Leonidas Stefanis, Erwan Bézard, Benjamin Dehay, Maria Xilouri

Peer-reviewed journal

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Increasing LAMP2A expression protected nigral dopaminergic neurons from LB-induced αSyn neurodegeneration, delayed the formation and release of pathology-related αSyn species, and evoked a beneficial effect on motor behavior and on cognitive functions of the primate model.
Limitation the authors admit
Our findings provide preliminary preclinical evidence supporting CMA enhancement as a therapeutic strategy for αSynucleinopathies.

Appeared: Sunday, November 1. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aeg1787